Skip to main content

Advertisement

Table 4 Median PFS (by RECIST) and median OS with other treatments for advanced SFT

From: Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Reference n = Regimen Front-line/ Further-line Median f-u (months) Median PFS (months) Median OS (months)
Stacchiotti [6] 31 Anthracycline-based chemo. 25/6 - 4 (range : 2–15) (front-line : 4) 11.5 (range : 3–50)
19 High dose ifosfamide single agent 11/8 - 3 (range : 2–9) (front-line : 3 (range : 2–9)) 11 (range : 3–50)
Park [5] 21a Conventional chemo. (anthracycline-based/gemcitabine-based/paclitaxel : 15/5/5) 18/7 - 4.6 (95 % CI = 3.7–5.6) (front-line: 4.6 (95 % CI = 4–5.3)) 22.8 (95 % CI = 3.1–42.6)
Stacchiotti [7] 8 Dacarbazine 0/8 - 7 (range : 2–12) -
Park [9] 14 Bevacizumab + temozolomide 9/5 34 10.8 (95 % CI = 8.13-not reached) 24.3
Stacchiotti [10] 35 Sunitinib 10/25 - 6 (95 % CI = 4.03–8.01) 16 (95 % CI = 12.07–25.9)
Valentin [11] 5 Sorafenib 0/5 - - 19.7
  1. f-u follow-up, PFS progression-free survival, OS overall survival
  2. aOf 21 patients, 4 received more than one regimen of chemotherapy, for a total of 25 treatments